• The infrastructure underneath global money movement is changing, and every company needs a stablecoin strategy of its own
  • Many of the companies actually starting to use stablecoins are not crypto start-ups but traditional businesses, and waiting carries a cost of its own
  • A stablecoin strategy can start with a small-scale pilot, and compliance must be taken seriously from day one

HONG KONG, Nov. 20, 2026 (GLOBE NEWSWIRE) — OSL Group (HKEX: 863) (“OSL”), a global stablecoin infrastructure company, has published an executive insight titled “Every Company Needs a Stablecoin Strategy,” authored by Kevin Cui, Executive Director and Chief Executive Officer.

In the article, Cui said the infrastructure underneath global money movement is changing. Just as every company needed an internet strategy when the internet era arrived twenty years ago, every company now needs a stablecoin strategy of its own.

Cui said that few companies turned into technology companies because of the internet, but many that moved early used it to make their traditional businesses better. Yet across the real economy, stablecoins are still widely seen as belonging to the crypto industry. Many companies assume that using stablecoins means holding volatile tokens, managing crypto wallets, or even turning into a Web3 business.

Cui noted that among the companies he meets, many of those actually starting to use stablecoins are not crypto start-ups but traditional businesses such as logistics firms, travel platforms and brands. He believes that companies holding on to old assumptions will gradually lose ground to their peers, and that choosing to wait carries a cost of its own.

He added that a stablecoin strategy does not need to start with a big leap or a reorganization of the finance team. Instead, companies can assess where money movement causes them the most pain, run a small-scale pilot, and let the results guide what comes next. At the same time, companies must take compliance seriously from day one and, as they put their strategy into action, choose a partner with mature, comprehensive infrastructure. OSL recently published Develop a Stablecoin Strategy for Your Business, a practical guide for companies.

“Our mission at OSL is to make money move as freely as information,” Cui said. “The internet did that for information, and the companies that took it seriously early did not become technology companies. They rode that wave of change to become better at what they already did. The same will be true, in the years ahead, of the companies that start building a stablecoin strategy today.”

Read the full executive insight, “Every Company Needs a Stablecoin Strategy”.

About OSL

OSL Group (HKEX: 863) is a global stablecoin infrastructure company that strives to provide compliant and efficient digital financial infrastructure services globally, empowering enterprises, financial institutions and individuals to seamlessly exchange, pay, trade, and settle between fiat and digital currencies. Grounded in the core values of Open, Secure, and Liquid, it is committed to building a more efficient ecosystem that connects global markets and enables instant, seamless and compliant value movement worldwide. For media inquiries, please contact: media@osl.com

  • The infrastructure underneath global money movement is changing, and every company needs a stablecoin strategy of its own
  • Many of the companies actually starting to use stablecoins are not crypto start-ups but traditional businesses, and waiting carries a cost of its own
  • A stablecoin strategy can start with a small-scale pilot, and compliance must be taken seriously from day one

HONG KONG, Nov. 20, 2026 (GLOBE NEWSWIRE) — OSL Group (HKEX: 863) (“OSL”), a global stablecoin infrastructure company, has published an executive insight titled “Every Company Needs a Stablecoin Strategy,” authored by Kevin Cui, Executive Director and Chief Executive Officer.

In the article, Cui said the infrastructure underneath global money movement is changing. Just as every company needed an internet strategy when the internet era arrived twenty years ago, every company now needs a stablecoin strategy of its own.

Cui said that few companies turned into technology companies because of the internet, but many that moved early used it to make their traditional businesses better. Yet across the real economy, stablecoins are still widely seen as belonging to the crypto industry. Many companies assume that using stablecoins means holding volatile tokens, managing crypto wallets, or even turning into a Web3 business.

Cui noted that among the companies he meets, many of those actually starting to use stablecoins are not crypto start-ups but traditional businesses such as logistics firms, travel platforms and brands. He believes that companies holding on to old assumptions will gradually lose ground to their peers, and that choosing to wait carries a cost of its own.

He added that a stablecoin strategy does not need to start with a big leap or a reorganization of the finance team. Instead, companies can assess where money movement causes them the most pain, run a small-scale pilot, and let the results guide what comes next. At the same time, companies must take compliance seriously from day one and, as they put their strategy into action, choose a partner with mature, comprehensive infrastructure. OSL recently published Develop a Stablecoin Strategy for Your Business, a practical guide for companies.

“Our mission at OSL is to make money move as freely as information,” Cui said. “The internet did that for information, and the companies that took it seriously early did not become technology companies. They rode that wave of change to become better at what they already did. The same will be true, in the years ahead, of the companies that start building a stablecoin strategy today.”

Read the full executive insight, “Every Company Needs a Stablecoin Strategy”.

About OSL

OSL Group (HKEX: 863) is a global stablecoin infrastructure company that strives to provide compliant and efficient digital financial infrastructure services globally, empowering enterprises, financial institutions and individuals to seamlessly exchange, pay, trade, and settle between fiat and digital currencies. Grounded in the core values of Open, Secure, and Liquid, it is committed to building a more efficient ecosystem that connects global markets and enables instant, seamless and compliant value movement worldwide. For media inquiries, please contact: media@osl.com

 AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
20 NOVEMBER 2026

RICHEMONT’S 2026 INTERIM REPORT NOW AVAILABLE ONLINE

Richemont announces the publication of its interim report and accounts for the six-month period ended 30 September 2026. The report is available for download from the Richemont website at: www.richemont.com/investors/results-reports-presentations/

The interim report reflects the information contained in the Richemont results announcement issued on 13 November 2026 as well as the unaudited condensed interim consolidated financial statements posted on the Group’s website the same day.

In accordance with stock exchange regulations in Switzerland and South Africa, Richemont no longer prints its interim report.

About Richemont

At Richemont, we craft the future. Our unique portfolio includes prestigious Maisons distinguished by their creativity and craftsmanship. Richemont’s ambition is to nurture its Maisons and businesses and enable them to grow and prosper in a responsible, sustainable manner over the long term.

Richemont operates in three business areas: Jewellery Maisons with Buccellati, Cartier, Van Cleef & Arpels and Vhernier; Specialist Watchmakers with A. Lange & Söhne, IWC Schaffhausen, Jaeger-LeCoultre, Panerai, Piaget, Roger Dubuis and Vacheron Constantin; and Other, primarily Fashion & Accessories Maisons with Alaïa, Chloé, Delvaux, dunhill, G/FORE, Gianvito Rossi, Montblanc, Peter Millar, Purdey, Serapian as well as TimeVallée and Watchfinder & Co. Find out more at https://www.richemont.com/.

Investor/analyst and media enquiries

Investor/analyst enquiries: +41 22 721 30 03; investor.relations@cfrinfo.net
Media enquiries: pressoffice@cfrinfo.net; richemont@teneo.com

Click here for a printer-friendly version in English (PDF)

 AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
20 NOVEMBER 2026

RICHEMONT’S 2026 INTERIM REPORT NOW AVAILABLE ONLINE

Richemont announces the publication of its interim report and accounts for the six-month period ended 30 September 2026. The report is available for download from the Richemont website at: www.richemont.com/investors/results-reports-presentations/

The interim report reflects the information contained in the Richemont results announcement issued on 13 November 2026 as well as the unaudited condensed interim consolidated financial statements posted on the Group’s website the same day.

In accordance with stock exchange regulations in Switzerland and South Africa, Richemont no longer prints its interim report.

About Richemont

At Richemont, we craft the future. Our unique portfolio includes prestigious Maisons distinguished by their creativity and craftsmanship. Richemont’s ambition is to nurture its Maisons and businesses and enable them to grow and prosper in a responsible, sustainable manner over the long term.

Richemont operates in three business areas: Jewellery Maisons with Buccellati, Cartier, Van Cleef & Arpels and Vhernier; Specialist Watchmakers with A. Lange & Söhne, IWC Schaffhausen, Jaeger-LeCoultre, Panerai, Piaget, Roger Dubuis and Vacheron Constantin; and Other, primarily Fashion & Accessories Maisons with Alaïa, Chloé, Delvaux, dunhill, G/FORE, Gianvito Rossi, Montblanc, Peter Millar, Purdey, Serapian as well as TimeVallée and Watchfinder & Co. Find out more at https://www.richemont.com/.

Investor/analyst and media enquiries

Investor/analyst enquiries: +41 22 721 30 03; investor.relations@cfrinfo.net
Media enquiries: pressoffice@cfrinfo.net; richemont@teneo.com

Click here for a printer-friendly version in English (PDF)

Geneva, Switzerland, November 20, 2026 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its 2026 Third Quarter Financial Results on November 25, 2026. Tim Dyer, CEO, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 10:00 EDT / 07:00 PDT) on November 25, 2026.

Title:  Addex Therapeutics Reports 2026 Third Quarter financial results and Provides Corporate Update
Date: November 25, 2026
Time: 16:00 CET (15:00 BST / 10:00 EST / 07:00 PST)

Joining the Conference Call:

  1. Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.
  2. In the 10 minutes prior to the call start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number.

Webcast registration link: Registration webcast

Conference call registration link: Registration conference media

About Addex Therapeutics

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. In addition, Addex  is advancing a differentiated GABAB PAM compound for the treatment of chronic cough. Addex holds an 8.5% equity interest in a private spin out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders and mGlu7 NAM for mood disorders. Addex has also invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders.

Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com.
  
Contacts: 

Tim Dyer 
Chief Executive Officer 
Telephone: +41 22 884 15 55 
PR@addextherapeutics.com 
Mike Sinclair 
Partner, Halsin Partners 
+44 (0)7968 022075 
msinclair@halsin.com 

Addex Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Geneva, Switzerland, November 20, 2026 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its 2026 Third Quarter Financial Results on November 25, 2026. Tim Dyer, CEO, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 10:00 EDT / 07:00 PDT) on November 25, 2026.

Title:  Addex Therapeutics Reports 2026 Third Quarter financial results and Provides Corporate Update
Date: November 25, 2026
Time: 16:00 CET (15:00 BST / 10:00 EST / 07:00 PST)

Joining the Conference Call:

  1. Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.
  2. In the 10 minutes prior to the call start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number.

Webcast registration link: Registration webcast

Conference call registration link: Registration conference media

About Addex Therapeutics

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. In addition, Addex  is advancing a differentiated GABAB PAM compound for the treatment of chronic cough. Addex holds an 8.5% equity interest in a private spin out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders and mGlu7 NAM for mood disorders. Addex has also invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders.

Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com.
  
Contacts: 

Tim Dyer 
Chief Executive Officer 
Telephone: +41 22 884 15 55 
PR@addextherapeutics.com 
Mike Sinclair 
Partner, Halsin Partners 
+44 (0)7968 022075 
msinclair@halsin.com 

Addex Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Louvain-la-Neuve, Belgium, November 20, 2026, 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, today announced the sale of the first Rhodotron® LITE X-ray irradiation system, shortly after its market launch. The system will be installed at an irradiation service center in Guangdong Province, in southern China.

Once installed, the system will provide comprehensive irradiation technologies for the South China region, maximizing the ability to meet the diverse needs of customers in Guangdong.

Rhodotron® LITE delivers processing capabilities equivalent to a gamma irradiation system with a Cobalt 60 activity of more than one million curies. It offers moderate annual throughput and extremely broad product adaptability, so it can serve as a parallel alternative to a wide range of gamma systems worldwide with 1–2 million curies of Cobalt 60.

Cobalt 60 is becoming less and less accessible, and its prices remain high globally. X-ray technology has emerged as a new solution for the irradiation industry, combining sustainability with good economic viability for the future. Rhodotron® LITE comprehensively surpasses gamma systems in terms of cost-effectiveness and sustainability and avoids the environmental burden associated with Cobalt 60. By strategically deploying X-ray technology, IBA is meeting increasingly diversified industrial demands and further consolidating its leading position in the irradiation services sector in China.

“This rapid first sale, so soon after the launch, confirms our strategic direction of offering smaller-scale X-ray solutions that give customers a first access to X-ray sustainable technology and help address the difficulties the market faces in sourcing cobalt. This solution will facilitate access to X-ray technology in China, where it will promote technological diversification and serve as a concrete implementation of the high-quality development philosophy and the ‘Healthy China’ strategy, but also in other countries, particularly developing countries,” said Thomas Servais, President of IBA Industrial.

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered to be one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

CONTACTS

Thomas Pevenage
Investor Relations
+32 10 475 890
investorrelations@iba-group.com

Nathalie van Ypersele
Head of Communication and Sustainability

Daniel Ernult
Corporate Communication Manager
+32 10 475 890
communication@iba-group.com

Attachment

Louvain-la-Neuve, Belgium, November 20, 2026, 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, today announced the sale of the first Rhodotron® LITE X-ray irradiation system, shortly after its market launch. The system will be installed at an irradiation service center in Guangdong Province, in southern China.

Once installed, the system will provide comprehensive irradiation technologies for the South China region, maximizing the ability to meet the diverse needs of customers in Guangdong.

Rhodotron® LITE delivers processing capabilities equivalent to a gamma irradiation system with a Cobalt 60 activity of more than one million curies. It offers moderate annual throughput and extremely broad product adaptability, so it can serve as a parallel alternative to a wide range of gamma systems worldwide with 1–2 million curies of Cobalt 60.

Cobalt 60 is becoming less and less accessible, and its prices remain high globally. X-ray technology has emerged as a new solution for the irradiation industry, combining sustainability with good economic viability for the future. Rhodotron® LITE comprehensively surpasses gamma systems in terms of cost-effectiveness and sustainability and avoids the environmental burden associated with Cobalt 60. By strategically deploying X-ray technology, IBA is meeting increasingly diversified industrial demands and further consolidating its leading position in the irradiation services sector in China.

“This rapid first sale, so soon after the launch, confirms our strategic direction of offering smaller-scale X-ray solutions that give customers a first access to X-ray sustainable technology and help address the difficulties the market faces in sourcing cobalt. This solution will facilitate access to X-ray technology in China, where it will promote technological diversification and serve as a concrete implementation of the high-quality development philosophy and the ‘Healthy China’ strategy, but also in other countries, particularly developing countries,” said Thomas Servais, President of IBA Industrial.

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered to be one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

CONTACTS

Thomas Pevenage
Investor Relations
+32 10 475 890
investorrelations@iba-group.com

Nathalie van Ypersele
Head of Communication and Sustainability

Daniel Ernult
Corporate Communication Manager
+32 10 475 890
communication@iba-group.com

Attachment

DUBAI, United Arab Emirates and WUHU, China, Nov. 20, 2026 (GLOBE NEWSWIRE) — LEPAS, Chery Auto’s Premium NEV brand, officially launched in the Middle East with a brand event in Dubai themed “Elegance Unbound” on November 18. The event brought together the LEPAS L8, L6 and L4 for their first joint showcase in the Gulf, with the L8 PHEV set to lead the brand’s market rollout across Middle Eastern markets.

LEPAS Debuts Tts Full Model lineup In The Middle East Market

[LEPAS Debuts Its Full Model lineup In The Middle East Market]

“Elegance transcends boundaries while reflecting local cultures. Through design, we connect different aesthetic perspectives; through technology, we bring confidence and peace of mind. We look forward to working with people across the Middle East to make elegance part of everyday life,” said Zhai Xiaobing, CEO of LEPAS.

Zhai Xiaobing, CEO of LEPAS

[ Zhai Xiaobing, CEO of LEPAS]

Building Local Connections Across the Middle East

LEPAS plans to establish lasting customer relationships through localized products, sales and service networks, and lifestyle collaborations. The L8 PHEV has completed 10,000 kilometres of road testing across several Gulf countries, combining a spacious cabin and extended range for daily commutes, intercity travel and longer road trips. The L4 will focus on agile urban mobility, while the L6 will offer intelligent technology and everyday comfort. All three will launch in phases across Gulf markets.

Scenes From The Middle East Brand Launch Event

[Scenes From The Middle East Brand Launch Event]

Over the next two years, LEPAS plans six models spanning A–D segments, including plug-in hybrid and hybrid powertrains, with future launches tailored to local market needs and customer lifestyles.

LEPAS L8 PHEV

[ LEPAS L8 PHEV]

Working with regional partners, LEPAS will expand its sales and after-sales network, giving customers access to vehicle experiences, purchasing services and ongoing support. A Jebel Ali parts warehouse will serve six Gulf countries, targeting a 48-hour response to spare-parts requests. Partnerships with regional creators and automotive media, participation in platforms including EV WORLD, and customer experiences in shopping and lifestyle destinations will strengthen local engagement.

Making Elegance Unbound a Local Experience

Following launches in Southeast Asia and Europe in 2026, LEPAS’s Middle East entry advances its global expansion. “Elegance Unbound” expresses a balance between consistent global design and quality standards and the cultural identities of individual markets. By listening to local customers and embracing different perspectives, LEPAS aims to create an expression of elegance that feels distinctive to each market while remaining true to its global identity.

Scenes From The Middle East Brand Launch Event

[Scenes From The Middle East Brand Launch Event]

About LEPAS

LEPAS is Chery Auto’s Premium NEV brand, dedicated to creating elegant mobility experiences for users worldwide. Committed to becoming the Preferred Brand for Elegant Mobility Life, LEPAS brings together Leopard Aesthetics, Elegant Technology, and Exquisite Space – transforming elegance into a driving experience you can see, feel, and trust. Supported by a growing global dealer network of more than 500 sales and service outlets, LEPAS is expanding its international footprint through localized operations, delivering products and experiences tailored to users across global markets.

About Chery Auto

Founded in 1997, Chery Auto is a global automotive manufacturer specializing in vehicle development, intelligent technologies, and new energy solutions. The company operates in more than 130 countries and regions, supported by a strong international network of research, production, and strategic partnerships. Chery Auto has remained China’s No. 1 passenger vehicle exporter among Chinese brands for 23 consecutive years. Guided by its global philosophy of “In somewhere, For somewhere, Be somewhere,” Chery Auto is committed to advancing sustainable mobility through continuous innovation and global collaboration.

Media Contact
Company Name: LEPAS International
Contact Person: Vincy wang
E-mail: GlobalPR@lepasinternational.com
Company Official Website: https://lepasinternational.com/

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/2a385389-5eec-401e-867d-a9762b213d67

https://www.globenewswire.com/NewsRoom/AttachmentNg/a98b50d9-7e3d-4c59-b4cb-a7da753dabdd

https://www.globenewswire.com/NewsRoom/AttachmentNg/253a2830-f1e2-4f31-bdf5-cf9b8bd1a929

https://www.globenewswire.com/NewsRoom/AttachmentNg/0c20b3fe-2cd8-4ebf-9174-b4a603200645

https://www.globenewswire.com/NewsRoom/AttachmentNg/dc8729d0-c6ab-4d1d-9b4d-bbf59ea86659

ATHENS, Greece, Nov. 20, 2026 (GLOBE NEWSWIRE) — Reference is made to the key information relating to Q3 2026 dividend announced by Okeanis Eco Tankers Corp. (“OET” or the “Company”) (NYSE: ECO / OSE: OET) on November 11, 2026. The Company’s common shares will be traded ex dividend USD 7.00 per common share on the Oslo Stock Exchange from today, November 20, 2026 and on the New York Stock Exchange from November 23, 2026.

Contacts

Company:
Iraklis Sbarounis, CFO
Tel: +30 210 480 4200
ir@okeanisecotankers.com

Investor Relations / Media Contact:
Nicolas Bornozis, President
Capital Link, Inc.
230 Park Avenue, Suite 1540, New York, N.Y. 10169
Tel: +1 (212) 661-7566
okeanisecotankers@capitallink.com

About OET
OET is a leading international tanker company providing seaborne transportation of crude oil and refined products. The Company was incorporated on April 30, 2018 under the laws of the Republic of the Marshall Islands and is listed on Oslo Stock Exchange under the symbol OET and the New York Stock Exchange under the symbol ECO. The sailing fleet consists of ten modern scrubber-fitted Suezmax tankers and eight modern scrubber-fitted VLCC tankers.

Forward Looking Statements
This communication contains “forward-looking statements”, including as defined under U.S. federal securities laws. Forward-looking statements provide the Company’s current expectations or forecasts of future events. Forward-looking statements include statements about the Company’s expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts or that are not present facts or conditions. Words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “hope,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. The Company’s actual results could differ materially from those anticipated in forward-looking statements for many reasons, including as described in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, you should not unduly rely on these forward-looking statements, which speak only as of the date of this communication. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s operating or financial results; the Company’s liquidity, including its ability to service its indebtedness; competitive factors in the market in which the Company operates; shipping industry trends, including charter rates, vessel values and factors affecting vessel supply and demand; future, pending or recent acquisitions and dispositions, business strategy, areas of possible expansion or contraction, and expected capital spending or operating expenses; risks associated with operations; broader market impacts arising from war (or threatened war) or international hostilities; risks associated with pandemics, including effects on demand for oil and other products transported by tankers and the transportation thereof; and other factors listed from time to time in the Company’s filings with the SEC. Except to the extent required by law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based. You should, however, review the factors and risks the Company describes in the reports it files and furnishes from time to time with the SEC, which can be obtained free of charge on the SEC’s website at www.sec.gov.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.